155 related articles for article (PubMed ID: 36160401)
1. Case report: Uridine triacetate in the management of delayed onset 5-fluorouracil toxicity: A case report and review of literature.
Jacob A; Sekkath Veedu J; Selene I; Raj R; Kannan L; Patel R
Front Pharmacol; 2022; 13():977734. PubMed ID: 36160401
[TBL] [Abstract][Full Text] [Related]
2. Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity.
Ma WW; Saif MW; El-Rayes BF; Fakih MG; Cartwright TH; Posey JA; King TR; von Borstel RW; Bamat MK
Cancer; 2017 Jan; 123(2):345-356. PubMed ID: 27622829
[TBL] [Abstract][Full Text] [Related]
3. Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency.
Saif MW; Diasio RB
Cancer Chemother Pharmacol; 2016 Jul; 78(1):151-6. PubMed ID: 27278667
[TBL] [Abstract][Full Text] [Related]
4. FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs.
Ison G; Beaver JA; McGuinn WD; Palmby TR; Dinin J; Charlab R; Marathe A; Jin R; Liu Q; Chen XH; Ysern X; Stephens O; Bai G; Wang Y; Dorff SE; Cheng J; Tang S; Sridhara R; Pierce W; McKee AE; Ibrahim A; Kim G; Pazdur R
Clin Cancer Res; 2016 Sep; 22(18):4545-9. PubMed ID: 27401247
[TBL] [Abstract][Full Text] [Related]
5. Prompt treatment with uridine triacetate improves survival and reduces toxicity due to fluorouracil and capecitabine overdose or dihydropyrimidine dehydrogenase deficiency.
Garcia RAG; Saydoff JA; Bamat MK; von Borstel RW
Toxicol Appl Pharmacol; 2018 Aug; 353():67-73. PubMed ID: 29908244
[TBL] [Abstract][Full Text] [Related]
6. Fluoropyrimidine-induced toxicity and DPD deficiency.. A case report of early onset, lethal capecitabine-induced toxicity and mini review of the literature. Uridine triacetate: Efficacy and safety as an antidote. Is it accessible outside USA?
Lampropoulou DI; Laschos K; Amylidi AL; Angelaki A; Soupos N; Boumpoucheropoulos S; Papadopoulou E; Nanou E; Zidianakis V; Nasioulas G; Fildissis G; Aravantinos G
J Oncol Pharm Pract; 2020 Apr; 26(3):747-753. PubMed ID: 31382864
[TBL] [Abstract][Full Text] [Related]
7. Two patients with fluoropyrimidine overdose successfully managed without uridine triacetate.
Kats CJ; Jochems A; Jeurissen FJ; Ledeboer A; van den Berg RB
J Oncol Pharm Pract; 2023 Dec; 29(8):2037-2040. PubMed ID: 37499216
[TBL] [Abstract][Full Text] [Related]
8. Case report of capecitabine toxicity and use of uridine triacetate.
Oliver WD; Duffy AP; Hausner PF
J Oncol Pharm Pract; 2019 Mar; 25(2):470-473. PubMed ID: 28942723
[TBL] [Abstract][Full Text] [Related]
9. Early-Onset 5-Fluorouracil Toxicity in a Patient Negative for Dihydropyrimidine Dehydrogenase Mutations: The Clinical Course of Reversal with Uridine Triacetate.
Vaudo CE; Gil B; Galuski K; Zarwan C; Nugent FW
Pharmacotherapy; 2016 Nov; 36(11):e178-e182. PubMed ID: 27716991
[TBL] [Abstract][Full Text] [Related]
10. Successful use of uridine triacetate (Vistogard) three weeks after capecitabine in a patient with homozygous dihydropyrimidine dehydrogenase mutation: A case report and review of the literature.
Zurayk M; Keung YK; Yu D; Hu EH
J Oncol Pharm Pract; 2019 Jan; 25(1):234-238. PubMed ID: 28950804
[TBL] [Abstract][Full Text] [Related]
11. The successful treatment of 5-fluorouracil (5-FU) overdose in a patient with malignancy and HIV/AIDS with uridine triacetate.
Santos C; Morgan BW; Geller RJ
Am J Emerg Med; 2017 May; 35(5):802.e7-802.e8. PubMed ID: 27884585
[TBL] [Abstract][Full Text] [Related]
12. Capecitabine-induced cerebellar toxicity and TYMS pharmacogenetics.
Saif MW
Anticancer Drugs; 2019 Apr; 30(4):431-434. PubMed ID: 30875351
[TBL] [Abstract][Full Text] [Related]
13. Uridine triacetate for severe 5-fluorouracil toxicity in a patient with thymidylate synthase gene variation: Potential pharmacogenomic implications.
Baldeo C; Vishnu P; Mody K; Kasi PM
SAGE Open Med Case Rep; 2018; 6():2050313X18786405. PubMed ID: 30013790
[TBL] [Abstract][Full Text] [Related]
14. Severe adverse events due to dihydropyrimidine dehydrogenase deficiency in a Japanese patient with colon cancer taking capecitabine: a case report.
Tsutsui M; Yamamoto S; Yoshikawa Y; Nakanishi R; Takano K; Osumi K; Akatsu T; Yoneyama K; Nakagawa M; Kanai T
Int Cancer Conf J; 2018 Oct; 7(4):125-129. PubMed ID: 31149530
[TBL] [Abstract][Full Text] [Related]
15. Use of uridine triacetate for the management of fluorouracil overdose.
McEvilly M; Popelas C; Tremmel B
Am J Health Syst Pharm; 2011 Oct; 68(19):1806-9. PubMed ID: 21930638
[TBL] [Abstract][Full Text] [Related]
16. Severe toxicity of capecitabine in a patient with DPD deficiency after a safe FEC-100 experience: why we should test DPD deficiency in all patients before high-dose fluoropyrimidines.
Maillard M; Eche-Gass A; Ung M; Brice A; Marsili S; Montastruc M; Puisset F; Thomas F
Cancer Chemother Pharmacol; 2021 Apr; 87(4):579-583. PubMed ID: 33587160
[TBL] [Abstract][Full Text] [Related]
17. 5-Fluorouracil Neurotoxicity in a Patient With Normal Dihydropyrimidine Dehydrogenase Activity.
Natarajan U; Onyechi A; Ohemeng-Dapaah J
Cureus; 2023 Dec; 15(12):e49898. PubMed ID: 38174188
[TBL] [Abstract][Full Text] [Related]
18. 5-Fluorouracil and Capecitabine: Assessment and Treatment of Uncommon Early-Onset Severe Toxicities Associated With Administration.
Brutcher E; Christensen D; Hennessey Smith M; Koutlas JB; Sellers JB; Timmons T; Thompson J
Clin J Oncol Nurs; 2018 Dec; 22(6):627-634. PubMed ID: 30451997
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
[TBL] [Abstract][Full Text] [Related]
20. Fluoropyrimidine-induced cardiotoxicity.
Depetris I; Marino D; Bonzano A; Cagnazzo C; Filippi R; Aglietta M; Leone F
Crit Rev Oncol Hematol; 2018 Apr; 124():1-10. PubMed ID: 29548480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
